- Israel hits symbols of Hamas rule; scores killed
- Mississippi abortion law can’t be enforced
- Teacher who survived Sandy Hook has book deal
- Jury awards Jesse Ventura $1.8M in case vs. ‘American Sniper’ author Chris Kyle
- Government OKs Arab-owned company to operate U.S. cargo port
- Bob McDonnell’s defense: Lonely wife developed ‘crush’ on CEO
- Chinese hackers stole ‘huge quantities’ of sensitive data on Israel’s Iron Dome
- House Republicans unveil bill to speed deportations of border children
- Californians protest middle school for hiring white man to teach cultural studies
- Killer’s sentencing overturned because mother couldn’t find seat in courtroom
PITTS: Dangers of worsening drug shortages
Remedy unavailability could start costing American lives
Question of the Day
All of sudden, the mainstream media - highlighted by a high-profile NewYorkTimespiece by bioethicist Dr. Zeke Emanuel- has discovered the problem of drug shortages. Except it’s not a new problem. According to a recent analysis, the frequency and
impact of drug shortages have risen to critical levels - more than tripling since 2005 - and shortages affect all segments of the health care sector. In 2010, more than 240 drugs were either in short supply or unavailable and more than 400 generic equivalents were back-ordered for more than five days. In most instances, these did not progress to critical shortages, but they point to instabilities in the supply chain that cause national concern. Many of the drugs identified in 2010 remain unavailable or in short supply in 2011.
Seventy-seven percent of drugs in short supply in 2010 were sterile injectable products - critical in the acute care setting. Recent media coverage highlights the plight of patients and physicians faced with shortages for cancer drugs, anesthetic agents and critical care medications that have contributed to delays in treatment and surgery or changes in care plans. Drug back orders cause patients to receive substitute therapies that add expense to patient care.
Among the major reasons for shortages are manufacturing-quality issues. However, there are other reasons, such as production delays at the manufacturer and delays companies have experienced receiving raw materials and components from suppliers. Discontinuation is another factor contributing to shortages.
In 2010, 178 drug shortages were reported to the FDA. Is that a solid number? It’s hard to say because current regulations do not require companies to notify the FDA of shortages. The only requirement is that companies inform the FDA six months in advance for discontinuations of sole-source medically necessary drugs.
In 2010, for example, 38 shortages were prevented by companies voluntarily notifying the FDA of potential issues that could lead to shortages; the agency was able to work with the companies to avoid shortages.
Inside the FDA’s Center for Drug Evaluation and Research resides the agency’s Drug Shortage Program. The program was established to address potential or actual shortages of drugs that have a significant impact on public health. Through communication, facilitation and negotiation, the program works with pharmaceutical manufacturers, and components of FDA to manage product shortages.
For example, when the drug shortage involves a generic product, the FDA works with other firms making the drug to help them ramp up production if they are willing to do so. Often they need new production lines approved or need new raw-material sources approved to help increase supplies. The FDA can and does expedite review of these to help resolve shortages of medically necessary drugs.
But the FDA can’t require the other firms to increase or commence production.
The agency tries to do the best it can with limited authority, spare resources and shared staff. In addition to direct communication with industry, the Drug Shortage Program also gets reports from health care professionals, patients and professional organizations using the email address email@example.com.
But, as you can imagine, there is not a lot of email traffic. And there is no social-media effort to promote the program’s purpose or existence.
The Institute for Safe Medication Practices reports that in a survey of 1,800 health care practitioners, more than half said they frequently or always encounter difficulties associated with drug shortages.
The top three problems fall squarely within the zone of appropriate FDA attention and action:
© Copyright 2014 The Washington Times, LLC. Click here for reprint permission.
TWT Video Picks
Get Breaking Alerts
- Boehner rules out impeachment: 'Scam started by Democrats'
- Obama thanks Muslims for 'building the very fabric of our nation'
- Obama's brother wears Hamas scarf bearing anti-Israel slogans in photo
- Obama: 'Not a new Cold War,' but new Russia sanctions announced
- Smugglers, rainstorm combine to poke holes in border fence
- Federal judge grants 90-day stay in D.C. gun case
- PHILLIPS: Once-in-a-century stupidity
- D.C. seeks to stay judge's order allowing gun owners to carry in public
- Illegal immigrants demand representation in White House meetings
- PRUDEN: When the hangman botches the job